QT Prolongation Risk with Mosapride and Itopride
Neither mosapride nor itopride significantly prolong the QT interval at therapeutic doses, and both appear safer than older prokinetics like cisapride or domperidone. However, the evidence suggests itopride may carry a slightly higher risk than mosapride for ventricular arrhythmias in real-world use.
Evidence for Mosapride
Mosapride demonstrates minimal QT prolongation potential across multiple studies:
- Animal studies showed mosapride at extremely high doses (30 mg/kg/hr IV in rats, 30 mg/kg in guinea pigs) caused only slight, non-significant QT prolongation, whereas cisapride at much lower doses caused marked prolongation 1
- In conscious cats receiving 60 mg/kg twice daily for 7 days (producing plasma levels 100 times higher than therapeutic human doses), mosapride did not affect QT interval or QTc 1
- Drug interaction study with erythromycin (a CYP3A4 inhibitor known to increase risk with other prokinetics) showed a 1.6-fold increase in mosapride levels but no significant QT or QTc changes and no correlation between plasma levels and ECG parameters 2
Evidence for Itopride
Itopride shows a favorable safety profile in clinical studies but with some caveats:
- Two clinical trials in non-ulcer dyspepsia patients found no QT prolongation on ECG monitoring with itopride 50 mg three times daily for 2 weeks 3, 4
- However, a large population-based study (2,817 subjects) found itopride use was associated with increased risk of severe ventricular arrhythmia compared to non-use (adjusted IRR 1.486,95% CI 1.196-1.845) 5
- Importantly, domperidone showed lower risk than itopride for severe VA in this real-world study (adjusted IRR 0.548,95% CI 0.345-0.870) 5
Clinical Context from Guidelines
The 2023 Canadian Cardiovascular Society guidelines emphasize that antiemetics can prolong QT interval 6, though they don't specifically name mosapride or itopride. The guidelines recommend:
- Check www.crediblemeds.org before prescribing potential QT-prolonging drugs 6
- Consider baseline ECG if: electrolyte disturbance present, already on QT-prolonging drug, or initiating high-risk drug 6
- Risk increases when QTc exceeds 500 ms or drug increases QTc by >60-70 ms 6
Key Risk Factors to Assess
Before prescribing either drug, evaluate:
- Female sex (higher risk for acquired LQTS) 6
- Electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia) 6
- Concurrent QT-prolonging medications (macrolides, fluoroquinolones, antipsychotics, antidepressants) 6
- Renal impairment (affects drug clearance) 6
- Underlying structural heart disease 6
- Baseline QTc >450 ms in men or >460 ms in women
Practical Recommendations
For mosapride:
- Baseline ECG not routinely required in low-risk patients
- Safe even with CYP3A4 inhibitor co-administration
- Appears to be the safer choice between the two drugs
For itopride:
- Consider baseline ECG in patients with ≥2 risk factors
- Monitor for arrhythmia symptoms (palpitations, syncope, dizziness)
- The population study suggests real-world arrhythmia risk may be underestimated by clinical trials 5
Common pitfall: Clinical trials showing "no QT prolongation" may not capture rare but serious arrhythmic events that emerge in population-level data. The discrepancy between itopride's clean trial data 3, 4 and its association with ventricular arrhythmias in the population study 5 illustrates this limitation.
If choosing between the two: Mosapride appears preferable based on more robust safety data across multiple study designs, lack of drug interactions affecting QT risk, and absence of population-level arrhythmia signals.